A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy

Journal of Clinical Investigation

Volumn 121, Issue 4, 2011, Pages 1524-1534

  Narayanan, Priyadharshini ^a   Lapteva, Natalia ^a   Seethammagari, Mamatha ^a,b   Levitt, Jonathan M ^a   Slawin, Kevin M ^a,c   Spencer, David M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Diana Helis Henry Medical Research Foundation   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AP 1903; CD40 ANTIGEN; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE SWITCHING; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD40; CANCER VACCINES; DENDRITIC CELLS; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; ORGANIC CHEMICALS; PROTEIN ENGINEERING; TACROLIMUS BINDING PROTEIN 1A; TOLL-LIKE RECEPTORS;

EID: 79953308076     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI44327     Document Type: Article

References (58)

1. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419-426. (Pubitemid 47509552)
2. Tuyaerts S, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007;56(10):1513-1537. (Pubitemid 47094397)
3. Gabrilovich DI. Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther. 2002;4(5):452-458. (Pubitemid 36305037)
4. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195-1203. (Pubitemid 46718404)
5. Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol. 2005;6(2):163-170.
6. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-α- converting enzyme. Implications for CD40 signaling. J Biol Chem. 2003;278(35):32801-32809. (Pubitemid 37055721)
7. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251(4991):283-287. (Pubitemid 21916873)
8. Clackson T, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998;95(18):10437-10442. (Pubitemid 28413085)
9. Hanks BA, et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med. 2005;11(2):130-137. (Pubitemid 40321347)
10. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol. 1998;10(11):1593-1598. (Pubitemid 28502373)
11. Lapteva N, et al. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007;67(21):10528-10537. (Pubitemid 350070829)
12. Schulz O, et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity. 2000;13(4):453-462.
13. Ahonen CL, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004;199(6):775-784. (Pubitemid 38375197)
14. Dohnal AM, Luger R, Paul P, Fuchs D, Felzmann T. CD40 ligation restores type 1 polarizing capacity in TLR4 activated dendritic cells that have ceased interleukin-12 expression. J Cell Mol Med. 2009;13(8B):1741-1750.
15. Scarlett UK, et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 2009;69(18):7329-7337.
16. Gomez CR, et al. Advanced age exacerbates the pulmonary inflammatory response after lipopolysaccharide exposure. Crit Care Med. 2007;35(1):246-251. (Pubitemid 46035702)
17. Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997;65(8):3239-3247. (Pubitemid 27342405)
18. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628-1632. (Pubitemid 46982038)
19. Hasan UA, et al. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci U S A. 2007;104(19):8047-8052. (Pubitemid 47185873)
20. Beutler BA. TLRs and innate immunity. Blood. 2009;113(7):1399-1407.
21. Burns K, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem. 1998;273(20):12203-12209. (Pubitemid 28240584)
22. Kaisho T, Hoshino K, Iwabe T, Takeuchi O, Yasui T, Akira S. Endotoxin can induce MyD88-deficient dendritic cells to support Th2 cell differentiation. Int Immunol. 2002;14(7):695-700. (Pubitemid 34814629)
23. Miller CP, Blau CA. Using gene transfer to circumvent off-target effects. Gene Ther. 2008;15(10):759-764. (Pubitemid 351627359)
24. Kim YM, Brinkmann MM, Ploegh HL. TLRs bent into shape. Nat Immunol. 2007;8(7):675-677. (Pubitemid 46965341)
25. Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science. 2005;309(5734):581-585. (Pubitemid 41033635)
26. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med. 2003;197(2):263-268. (Pubitemid 36152320)
27. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394-397. (Pubitemid 27334820)
28. Hofer S, Rescigno M, Granucci F, Citterio S, Francolini M, Ricciardi-Castagnoli P. Differential activation of NF-κB subunits in dendritic cells in response to Gram-negative bacteria and to lipopolysaccharide. Microbes Infect. 2001;3(4):259-265. (Pubitemid 32385774)
29. O'Sullivan BJ, Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-κB. J Immunol. 2002;168(11):5491-5498. (Pubitemid 34556127)
30. Macagno A, Napolitani G, Lanzavecchia A, Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol. 2007;28(5):227-233. (Pubitemid 46654873)
31. Krug A, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31(10):3026-3037. (Pubitemid 32994554)
32. Lapointe R, Toso JF, Butts C, Young HA, Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol. 2000;30(11):3291-3298.
33. Morelli AE, et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood. 2001;98(5):1512-1523.
34. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest. 2006;116(1):90-100. (Pubitemid 43121794)
35. Yanagawa Y, Onoe K. Distinct regulation of CD40-mediated interleukin-6 and interleukin-12 productions via mitogen-activated protein kinase and nuclear factor ?B-inducing kinase in mature dendritic cells. Immunology. 2006;117(4):526-535.
36. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol. 2006;24(12):1581-1590. (Pubitemid 44967484)
37. Gallo P, Dharmapuri S, Cipriani B, Monaci P. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther. 2005;12(suppl 1):S84-S91. (Pubitemid 41541756)
38. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(3):295-304.
39. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther. 2009;17(8):1333-1339.
40. Allan RS, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity. 2006;25(1):153-162. (Pubitemid 44066832)
41. Martín-Fontecha A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003;198(4):615-621. (Pubitemid 37040395)
42. Allenspach EJ, Lemos MP, Porrett PM, Turka LA, Laufer TM. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity. 2008;29(5):795-806.
43. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133-146. (Pubitemid 37328691)
44. Fujita M, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res. 2009;69(4):1587-1595.
45. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci. 2002;27(9):474-482. (Pubitemid 35246257)
46. Biswas SK, et al. Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance. J Immunol. 2007;179(6):4083-4092.
47. De Trez C, et al. TLR4 and Toll-IL-1 receptor domain-containing adapter-inducing IFN-β, but not MyD88, regulate Escherichia coli-induced dendritic cell maturation and apoptosis in vivo. J Immunol. 2005;175(2):839-846. (Pubitemid 41094966)
48. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 1999;189(3):521-530.
49. Shen H, Tesar BM, Walker WE, Goldstein DR. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol. 2008;181(3):1849-1858.
50. Pettit AR, et al. Nuclear localization of RelB is associated with effective antigen-presenting cell function. J Immunol. 1997;159(8):3681-3691. (Pubitemid 127469621)
51. Clark GJ, Gunningham S, Troy A, Vuckovic S, Hart DN. Expression of the RelB transcription factor correlates with the activation of human dendritic cells. Immunology. 1999;98(2):189-196. (Pubitemid 29487639)
52. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009;30(10):475-487.
53. Divanovic S, et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005;6(6):571-578. (Pubitemid 41710727)
54. Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol. 2007;25(8):825-826. (Pubitemid 47236890)
55. Huang B, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65(12):5009-5014. (Pubitemid 40827306)
56. Berzofsky JA, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004;113(11):1515-1525. (Pubitemid 39071672)
57. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2(4):227-238. (Pubitemid 37323223)
58. Sancho D, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009;458(7240):899-903.